Analyst Ratings for Y-mAbs Therapeutics (YMAB) [Neutrals]
YMAB Rating Summary
YMAB Price Target Summary
- Highest: $26.00 (Canaccord Genuity)
- Lowest: $5.00 (Morgan Stanley)
- Average: $16.29
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$16.29 (+6.5%)
* Over Last 12-Mos
Rating Score: 5.5 / 10
Percentile Rank: 59%
Avg. $ Target:
$16.29 (+6.5%)
* Over Last 12-Mos
Rating Score: 5.5 / 10
Percentile Rank: 59%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/3/2023 | Guggenheim | Ezter Darout | Downgrade | Neutral (Buy) |
N/A (N/A) |
5.01 (15.29) |
205.19% | Details |
| 1/5/2023 | TD Cowen | Joe Thome | Downgrade | Hold (Buy) |
N/A (N/A) |
5.11 (15.29) |
199.22% | Details |
 |
||||||||
